By Kim Richters

Fresenius SE & Co. (FRE.XE) said Tuesday that its subsidiary Fresenius Kabi has formed a joint venture with pharma peers Bio-Techne Corp. (TECH) and Wilson Wolf.

The collaboration will focus on providing technology to develop and commercialize cell and gene therapies, German health-care company Fresenius said of its medicines division's venture.

The company didn't disclose any financial details of the joint venture, which is equally owned by the three parties.

Write to Kim Richters at kim.richters@wsj.com

(END) Dow Jones Newswires

January 21, 2020 09:09 ET (14:09 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.
Fresenius SE & Co KGaA (TG:FRE)
Historical Stock Chart
Von Mär 2024 bis Apr 2024 Click Here for more Fresenius SE & Co KGaA Charts.
Fresenius SE & Co KGaA (TG:FRE)
Historical Stock Chart
Von Apr 2023 bis Apr 2024 Click Here for more Fresenius SE & Co KGaA Charts.